The net worth or total market capitalization of Outlook Therapeutics fluctuates dynamically based on daily trading sessions on the Nasdaq exchange, hovering within the micro-cap range of $150 million to $165 million USD. This enterprise valuation reflects trailing capital raises, ongoing research and development expenditures, and investor sentiment regarding the commercial launch potential of its newly approved flagship ophthalmic treatments.